Home
HelpTest Code Billings Clinic: 0152 Mayo: DHTS Dihydrotestosterone, Serum
Reporting Name
Dihydrotestosterone, SPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Useful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Type
SerumSpecimen Minimum Volume
0.6 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 90 days | ||
| Ambient | 28 days |
Reject Due To
| Gross hemolysis | OK |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
|
Mean |
Age |
Reference range (pg/mL) |
|
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
|
Stage II |
12.1 years |
≤200 |
|
Stage III |
13.6 years |
80-330 |
|
Stage IV |
15.1 years |
220-520 |
|
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
|
Mean |
Age |
Reference range (pg/mL) |
|
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
|
Stage II |
10.5 years |
≤300 |
|
Stage III |
11.6 years |
≤300 |
|
Stage IV |
12.3 years |
≤300 |
|
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Interpretation
Patients taking 5-alpha reductase inhibitor have decreased dihydrotestosterone (DHT) serum levels.
Patients with genetic 5-alpha reductase deficiency (a rare disease) also have reduced DHT serum levels.
DHT should serve as the primary marker of peripheral androgen production. However, because it is metabolized rapidly and has a very high affinity for sex hormone-binding globulin, DHT does not reflect peripheral androgen action. Instead, its distal metabolite, 3-alpha, 17-beta-androstanediol glucuronide, serves as a better marker of peripheral androgen action.
For more information see Steroid Pathways.
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 8 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82642
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| DHTS | Dihydrotestosterone, S | 1848-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 81479 | Dihydrotestosterone, S | 1848-1 |
Testing Algorithm
For more information see Steroid Pathways.